Novel and Potent MICA/B Antibody Is Therapeutically Effective in KRAS LKB1 Mutant Lung Cancer Models

Researchers evaluated NK cell activating therapy agents specifically in KRAS LKB1 mutant NSCLC, revealing that effectively engaging multiple potent NK activating receptors enhanced NK cell cytotoxicity.